Category Archives: Rainbow Coral Corp. RBCC

Rainbow Coral Corp. (RBCC) Points to North American Substance Abuse as Catalyst for Much-Needed Solution

July 23, 2015

Rainbow Coral today highlighted substance abuse numbers from the United States and Canada as evidence of Naltrexone’s strong growth potential; the statistics also strengthen RBCC’s plans to aggressively pursue additional partners and distribution channels to get the anti-addiction drug into as many markets as possible.

“Drug and alcohol addiction afflicts millions of North Americans struggling to free themselves from this terrible disease,” RBCC CEO Kimberly Palmer stated in the news release. “The stats don’t paint a pretty picture regarding addiction, however they do represent a window for companies like ours to deliver treatments that will change lives for the better. That’s rewarding from a personal standpoint, and offers an opportunity to build a revenue stream to reward our investors on the business side.”

Wealthy and developed countries like the U.S. and Canada have the world’s highest rates of substance abuse. According to a 2013 survey, 9.4 percent of Americans have used illicit drugs in the past month, up from 8.3 percent in 2002, while approximately 14 million Americans, 7.4 percent of the population, meet the diagnostic criteria for alcoholism. Meanwhile, about 11 percent of Canadians are afflicted with alcohol or drug addiction.

Substance at this level abuse costs U.S. taxpayers USD $700 billion per year for treatment services, employing law enforcement and related equipment. Canadian taxpayers face a C$22.8 billion tab each year to the disease.

RBCC says it is nearing agreements with a Canadian medical group that utilizes Naltrexone to treat substance abuse, as well as with another company to distribute Naltrexone in Canada.

For more information visit

Rainbow Coral (RBCC) Discussing LOI with Canadian Medical Group Regarding Substance Abuse Treatment

July 21, 2015

The group has developed an effective program to help patients overcome their addiction to alcohol. This two-tiered program first employs medical intervention utilizing a proprietary formulation of Naltrexone then shifts to structured, personalized counseling. The medical intervention enables the addicted patient to end their cravings to drink while followup counseling addresses emotional needs.

The group has reported their unique approach has enjoyed unprecedented success helping people defeat their alcohol addiction.

“This group is doing some wonderful work assisting people to get their lives back from alcohol addiction,” said RBCC CEO Kimberly Palmer. “We are delighted and excited about the potential for good this growing relationship holds, not only for our investors, but for patients too. It falls perfectly into the focus of our important and meaningful research into addiction treatment.”

Substance abuse treatment in Canada, such as alcohol addiction, represents a USD 1 billion market, according to industry analysts. Research indicates Canadians are more at risk for alcohol abuse as they drink 50 percent more alcohol than the global average.

The medical group news follows closely behind RBCC’s proposed letter of intent with another company to distribute Naltrexone in Canada. RBCC has been aggressively pursuing business opportunities in Canada in recent months as the northern nation has proven to be a welcoming market for not only Naltrexone, but other RBCC pursuits such as personalized medicine and adult stem cell research as well.

For more information on RBCC’s initiatives, please visit

Rainbow Coral (RBCC) Optimistic of Naltrexone’s Growing Market Potential, Industry Acceptance

July 16, 2015

Biotech company Rainbow Coral Corp. (RBCC) reports its flagship drug Naltrexone continues to gain widespread acceptance in the medical world as researchers discover more and more practical and beneficial uses for it. As Naltrexone’s acceptance and usage spreads, RBCC expects to enjoy greater revenues from the drug.

“Naltrexone has proven to not only be an effective drug since its debut, but a very versatile one as well,” said RBCC CEO Kimberly Palmer. “And because it has been so beneficial and versatile, it’s also proven to be a product that can generate revenues as it is becoming a standard treatment for many afflictions. We’re optimistic these new markets and growing list of applications will add to the success we’ve had with the drug over the years.”

Initially developed as a means to combat alcohol and opioid addiction, some have found the drug in low doses can also an effective means to treat autoimmune diseases and maladies such as Crohn’s disease, fibromyalgia, chronic pain, and chronic fatigue syndrome. The result is that the market for Naltrexone, already considerable thanks to its successful use against alcohol dependence, could experience strong future growth as additional applications are found.

Drug, alcohol and other addiction rehab is a $35 billion industry in the U.S., with more than 14,000 treatment facilities and 2.5 million patients receiving treatment. Meanwhile, pharmaceutical analysts estimate the market for chronic pain medication to surpass $21 billion by 2022, while sales of Crohn’s disease drugs could top $5.6 billion by 2021, and fibromyalgia treatments may reach $1.9 billion by 2023.

Nano3D Technology Praised in Scientific Study on Three-Dimensional Cell Cultures

September 27, 2013

Rainbow Coral Corp. appeared in the news yesterday after a study published in the scientific journal Biochimica et Biophysica Acta reported on the superiority of three-dimensional cell cultures produced by the company’s partner, Nano3D Biosciences, over traditional two-dimensional cultures. RBCC and Nano3D have had a joint partnership since last year.

The illuminating study, undertaken by researchers from Houston’s Baylor College of Medicine and the Methodist Hospital Research Institute, reports on experiments that tested the transdifferentiation of vascular smooth muscle cells into calcifying vascular cells. The group used Nano3D’s Bio-Assembler technology to magnetically levitate their cell cultures in order to produce more lifelike tissues.

Researchers found that cells grew more rapidly using 3-D than 2-D. They also differentiated in days rather than weeks. The published piece is yet more evidence to the scientific community that the Bio-Assembler is an essential tool for all kinds of cellular research, including disease models.

RBCC’s CEO, Patrick Brown, remarked, “The Bio-Assembler represents a new evolution in cell culture technology. Thanks to high-profile research being conducted using this system, word is being spread very rapidly as to the unparalleled utility and efficiency afforded by the Bio-Assembler.”

For more information on RBCC, its partnership with Nano3D, and any of its initiatives, please visit

Let us hear your thoughts below:

Rainbow BioSciences Corp. (RBCC) Sees Canadian Market as Potential Opportunity to Expand Biotech Initiatives

July 30, 2013

As part of its broader strategy to secure a firm and competitive footing in the $232 billion personalized medicine market, Rainbow Coral Corp. has identified Canada as a potentially lucrative market for opportunities and partnerships that could lead to profitable new medical technologies and innovations.

“In spite of its world-class healthcare system, Canada remains a highly underdeveloped market for personalized medicine products, services and innovations,” RBCC CEO Patrick Brown stated in the press release. “Our research indicates that some forward-thinking investment there could lead to big returns for our company as we work to deliver new cutting-edge tools for the future of global medicine.”

RBCC is already executing an aggressive strategy for market penetration in the United States. The company recently signed a joint venture agreement with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform designed to make the local delivery of biologic agents and small molecules safer, more effective, and more convenient.

In addition, RBCC’s joint-venture partner, Nano3D BioSciences, has entered into a distribution agreement with St. Louis-based scientific products distributor MIDSCI to sell its revolutionary BioAssembler product line in the multi-billion-dollar U.S biotechnology market.

“It’s a wide-open market with unlimited potential for growth,” Brown said.

For more information visit

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) Partner n3D BioSciences Awards Up-and-Coming Scientists

July 23, 2013

Rainbow Coral today announced that one of its partners, Nano3D BioSciences, announced the winners of a scientific discovery competition called The MAD Scientist Contest by n3D. The competition was designed to introduce n3D’s groundbreaking 3D cell culturing technology to a budding generation of “MAD” scientists.

The top cash prize was awarded to Hamsa Jaganathan, Ph.D., of the Methodist Hospital Research Institute for her amazing model of a breast tumor microenvironment, created by co-culturing breast cancer cells and fibroblasts. Second prize went to Matthew Hogan at the University of Houston for his creation of a functional, or beating, primary cardiac cultures in vitro.

“The winning entries illustrate how 3-D, suspended cultures constructed using n3D technology improve data and achieve results impossible with other cell-culturing systems,” stated RBCC CEO Patrick Brown. “The MAD Scientist Contest also served to introduce n3D’s Bio-Assembler system to the young scientists who will undoubtedly lead cellular research into the future.”

This contest is a critical piece of n3D and RBCC’s strategy to build strong interest in the scientific and research communities. According to today’s press release, the system’s next-generation functionality enables production of accurate, 3D representations of in vivo tissues faster and easier than any other existing technology.

For additional information, visit

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) Partner Uses Pioneering Technology to Support the Delivery of Advanced Drugs

July 22, 2013

As a detailed understanding of the human body grows, it opens the door to a world of new drugs that involve much more complex molecules. These drugs, often simply called biologics, are the product of biological processes, and can be made up of such things as complex proteins or even living cells. These remarkable new drugs can biologically interact with living organisms in ways that simple molecules cannot. As such, they offer significant new therapeutic potential for many diseases and represent the leading edge in drug research. The drug filgrastim, for example, is a common biologic valuable for its ability to promote white blood cell growth, a critical part of certain cancer treatments.

But there’s a problem with biologics. Because of their molecular complexity, many of them cannot be taken orally. The human digestive process would break down the long molecules before they had a chance to perform their therapeutic function. As a result, biologics must almost always be given intravenously. However, in cases where multiple injections are required, that can mean having patients constantly traveling to a doctor’s office for unpleasant shots, or even having patients taking on the potentially risky process of administering shots themselves. Transdermal patches have been considered, but have limitations in the types of drugs the current technology can administer.

A flexible solution to the problem of giving needed non-oral drugs without shots is being addressed by TheraKine Ltd., a partner of Rainbow Coral. The company has developed an injectable sustained release technology that can allow any biological drug to be formulated for months of stability and controlled release. It’s a game-changing technology that can be applied to a variety of delivery approaches, such as topical use, local injection, depot forms, and even catheter or arthroscopic delivery.

RBCC has partnered with TheraKine to identify healthcare providers with potential clients for TheraKine’s new sustained-release delivery system.

For additional information, visit

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) Poised for Rapid Growth as Personalized Medicine Market Continues to Expand

July 11, 2013

Rainbow Coral Corp. is focused on delivering profitable new medical technologies and innovations. Targeting the fast-growing, $232 billion personalized medicine market, Rainbow Coral is well positioned for the future as the sector could nearly double to $452 billion by 2015, according to PricewaterhouseCoopers.

Today the company reports the rapid transition of molecular pathology tests from the laboratory to the clinic. GEN magazine recently said that clinical laboratories began billing for more than 100 molecular pathology tests using new CPT codes on the first of this year, replacing the previous stacked-code system. This development means the valuable testing will be available to more patients through their insurance providers, opening up personalized medicine to a much wider audience.

“We’re beginning to see patient care billers recognize that these tests work and provide value to the patient, the physician and the healthcare system,” stated RBCC CEO Patrick Brown. “That’s a big breakthrough: Insurance coverage decisions and physician test usage are big drivers of clinical utility.”

RBCC told investors it is developing a comprehensive media and marketing strategy designed to introduce new innovations and treatment options in the personalized medicine market. RBCC has formed a biotech subsidiary, Rainbow BioSciences, to market and develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN).

For more information on the company, please visit

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) Partner Successfully Raises Funds for New Drug Delivery Solutions

July 1, 2013

Today before the opening bell, Rainbow Coral applauded the fundraising results achieved by joint venture partner TheraKine, Ltd.

“TheraKine has done a tremendous job of bringing in outside funds to help push its innovations further into a hungry marketplace,” said RBCC CEO Patrick Brown. “The interest in TheraKine’s new drug delivery solutions is a fantastic illustration of this new system’s incredible market potential.”

Rainbow Coral signed a joint venture agreement with TheraKine earlier this year to help market and develop a revolutionary, sustained-release drug delivery platform designed to make local delivery of biologic agents and small molecules safer, more effective, and more convenient. TheraKine’s novel, patented technologies have the potential to enable selective, site-specific drug delivery, allowing for lower drug concentrations and significantly reducing the risk of drug toxicity.

As TheraKine concentrates on outside fundraising in order to market these technologies around the globe, RBCC is seeking out interested healthcare providers with clients that would highly value TheraKine’s advanced sustained-release delivery system.

The global market for drug delivery technologies is driven by biologics and medications that can’t be administered effectively through traditional means. Some experts believe that the worldwide market for the 10 most popular drug delivery technologies alone could grow to $81.5 billion by 2015.

RBCC is dedicated to delivering new medical research and technologies. For more information on RBCC’s initiatives, please visit

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) Partner Brings Space Down to Earth

June 24, 2013

One of Rainbow’s partner companies, Nano3D Biosciences (n3D), is bringing a bit of outer space down to earth, and it’s doing it for a good cause. The company has developed a way to simulate the weightlessness of outer space on a small scale, right in the lab, allowing researchers to better create and deal with 3-dimensional biological processes. With the company’s proprietary Bio-Assembler, special reagents deliver biocompatible magnetic nanoparticles to cells. Magnetic forces can then gently levitate and guide cells together as if they were weightless, to quickly induce cell-cell interactions in a true 3D environment as they would react in a living organism.

Space research has shown that reduced gravitational force can have a significant effect on cell growth and function, and can provide a superior way to work with and explore biological processes related to things such as cancer treatment. By presenting a way to duplicate the effects of space inside a controlled earthbound laboratory, n3D gives scientists an important new tool. In addition, the n3D system is very easy to use, and operates in standard petri dishes with virtually any cell and media type. It’s compatible with co-culturing, and standard imaging and diagnostic techniques. There are no special media requirements when culturing cells with their Bio-Assembler.

Cells grown in 2D mono-layers simply do not replicate the complex interactions and architecture found in living organisms, and this limits the effectiveness of basic life science research, toxicity testing, and drug discovery. The n3D system offers rapid formation of 3D structures and cell-cell interactions, more accurately representing the in vivo environment, and providing a unique capability for moving and shaping tissue. For more physiologically relevant results, the future clearly lies in 3D cell culturing.

For additional information, visit and

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) Partner Offers Cell Research Game Changer

June 17, 2013

Rainbow Coral’s partner, Nano3D Biosciences (n3D), is the creator of one of the newest 3D cell culturing technology on the market. Cells grown in 2D mono-layers simply do not replicate the complex interactions and architecture found in living organisms, which limits their use in basic life science research, toxicity testing, and drug discovery. n3D’s Bio-Assembler brings the simplicity of 2D culturing to 3D.

The company’s Bio-Assembler is as simple as standard 2D techniques and faster than any other 3D cell culturing product currently available. Preparation time and cell manipulation requirements are equivalent to 2D culture. In fact, there are only two additional steps that differentiate the Bio-Assembler’s innovative 3D cell culturing process from 2D cell culturing: (1) Adding the Nanoshuttle to cells prior to levitation, and (2) Placing the magnetic drive on top of the cell culture plate.

With the Bio-Assembler, easy-to-use reagents deliver biocompatible magnetic nanoparticles to cells, and magnetic forces gently levitate and guide cells together to quickly induce cell-cell interactions. It’s a process that mimics the in vivo environment, yet operates in standard petri dishes with virtually any cell and media type. It’s compatible with co-culturing, and standard imaging and diagnostic techniques.

There are important advantages offered by n3D’s cell culturing system:

• Rapid formation of 3D structures and cell-cell interactions
• More accurate representation of in vivo tissue
• Compatibility with virtually any cell type, including primary and stem cells
• Unique capability for moving and shaping tissue, applicable to invasion studies and tissue engineering
• Compatibility with any media type, standard culturing protocols, and diagnostic techniques

The company’s Bio-Assembler system works with virtually all cell types, including primary lung cells, glioblastoma cells, HUVEC cells, neural stem cells, liver cells, and breast cells. It also works with all standard protocols and diagnostics, including Fixing Tissue, Immunohistochemistry (Paraffin Embedded), Immunohistochemistry (Non-Embedded/Whole Mount), High Resolution Imaging, and Levitating Suspended Cells.

The technology is a game changer, to the extent that it was even written up in Nature, the world’s premiere science journal.

For additional information, visit and

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) Pursues Expansion and Explores New Funding

June 10, 2013

Rainbow Coral Corp. today told investors that it is considering new funding opportunities with promise in order to expand in the $232 billion personalized medicine market.

The company is pushing forward with its aggressive expansion strategy for this year and is already poised for rapid growth. The company recently signed a joint venture agreement with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective, and more convenient than ever before, and is currently in negotiations to partner with an emerging innovator in the transdermal delivery sector, as well. Last month, RBCC’s joint venture partner, Nano3D BioSciences, announced a distribution agreement with St. Louis-based scientific products distributor MIDSCI to sell its revolutionary BioAssembler product line in the multi-billion-dollar U.S biotechnology market.

“Our company is now well-positioned in a robust marketplace, and new funding opportunities are opening up for us every day,” said RBCC CEO Patrick Brown. “We’re carefully considering our options in order to ensure that we’re able to accomplish the goals that we’ve set for ourselves this year.”

Focused on expanding its marketing and development efforts, RBCC is fully committed to capitalizing on the unprecedented rise of the biotechnology sector.

For more information on RBCC’s partnership with n3D and other biotech initiatives, visit

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow BioSciences (RBCC) Continues Potential Partner Talks with Transdermal Patch Company

June 5, 2013

Rainbow Coral Corp., via wholly owned subsidiary Rainbow BioSciences, LLC, markets and develops new medical and research technology innovations through partnerships with biotech developers. Rainbow BioSciences is currently looking to partake in the $142 billion U.S. drug delivery market as it continues partnering talks with a transdermal patch company.

The transdermal delivery market is expected to increase up to $31.5 billion by 2015, and industry experts forecast the growth to continue as its applications extend to include many treatments, including nicotine addiction and Parkinson’s disease.

“Personalized medicine is the future,” RBCC CEO Patrick Brownstated in the press release. “This is an incredible breakthrough for any patient who doesn’t want to take pills or is afraid of needles. The transdermal patch empowers the patient to medicate on their schedule. It is perfect for our growing elderly population.” 

Transdermal patches are saturated with a specific medicine. Adhered directly to the skin, transdermal patches gradually dispense the medicine to the designated area of the body. The ease of use, reduced side effects, and other benefits, contribute to the growing popularity and application of transdermal patches. 

For more information

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) to Fuel Patient Demand for Personalized Medicine and Better Healthcare

May 30, 2013

Today before the opening bell, Rainbow Coral Corp. announced that it is making plans to empower patients to demand better care through both innovation and education as the company sets its sights on the fast-growing, $232 billion personalized medicine market.

By delivering new technologies in the sectors of the personalized medicine field expected to see the most growth, Rainbow Coral hopes to arm patients with more effective and efficient treatment options than ever before. But, according to today’s press release, bringing new ideas and products to the marketplace is only one piece of the company’s expansion strategy.

“Our ultimate goal is to help spur patient-driven demand for personalized medicine,” RBCC CEO Patrick Brown stated. “That requires not just delivering new innovations, but helping to educate patients on these promising new treatment options. That’s why we’re developing a comprehensive media and marketing strategy.”

PricewaterhouseCoopers projects that the personalized medicine market in the U.S. could grow to as much as $452 billion by 2015. One of the fastest-growing fields in the market is companion diagnostics, an area of RBCC’s focus, which could grow to as large as $42 billion by 2015, according to industry analysts

For more information, visit

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) Forging Ahead in Biotech Breakthroughs through Intelligent Partnerships

May 28, 2013

Rainbow Coral is carving off an ever larger slice of the biosciences pie with each passing day via shrewd partnering with key product and medical technology innovators, as well as via their wholly-owned biotech subsidiary, Rainbow BioSciences, LLC, as the biotech sector alone climbs steadily upwards of some $89.8B in revenues for 2012 (Ernst & Young, Biotech Industry Report 2013).

A leading example of this growth strategy by RBCC occurred in late March this year, as the company moved to form a strategic JV with the developer of an incredible sustained release drug delivery technology for biologics and other sensitive drugs, TheraKine. The TheraKine sustained release delivery platform offers a host of tunable options for extended duration and localized controlled release, whether it’s a six-month linear release or even a quick burst followed by slow release. The drug delivery space is a vital vector for RBCC’s overall strategy and the TheraKine deal is a classic example of how the company is positioning shareholders to profit off the development and commercialization of such highly sought after technologies.

More recently (May 21), RBCC took an even bolder step to capture space in the burgeoning, $142B plus U.S. drug delivery market by opening talks with a potentially key player in the transdermal delivery space working on patch technology. Transdermal patches offer several benefits over typical oral and intravenous methods, ranging from vastly improved bioavailability and longer duration, to greater safety/efficacy (with fewer side effects) and more uniform plasma levels. With estimates on the domestic transdermal delivery space alone upwards of $31.5B in just two year’s time, this deal with a potential leader in the sector could pan out into some serious upside for RBCC investors, especially considering the company’s overall biotech footprint.

One of the company’s most important partners, Nano3D Biosciences (n3D), the developers of an incredibly powerful BioAssembler product line that does 3D cell culture, allowing for researchers to generate extremely lifelike tissues which are nearly identical to those naturally occurring in the body, recently announced (May 13) a major U.S. distribution agreement. One of the big scientific product distributors, MIDSCI out of St. Louis, is intent on pumping out BioAssembler units to the eager domestic cell culture market, which stretches across the life sciences arena from academic and biotech research, to government and pharma.

This distribution deal comes on the heels of last year’s signing of a JV agreement between n3D and Rainbow BioSciences to help develop/market the BioAssembler technology and occurs amid a mounting level of excitement over the far-reaching potential of n3D’s magnetic levitation technology since being featured in the widely-read science journal Nature. When you have the top science journal on the planet calling your technology “the future of cellular research,” that is more than a PR jackpot, it’s something that kicks open the door to unquantifiable opportunities in the sector. There has been a blazing firestorm of coverage since the Nature publication in April’s issue and one look at the technology leaves investors with little to ponder about the potential massive impact of being able to create 3D tissues in the lab.

RBCC is a small company with a solid niche already carved out via its partnerships and the Rainbow BioSciences subsidiary in a much larger field that is dominated by majors like Amgen and Bristol Myers Squibb. With constantly evolving plans in the works, like an upcoming strategic partnership with a Houston-based genomics company that has an amazing 11 NASA-licensed patents that would give RBCC a solid foothold in genetic testing/personalized medicine, the company is growth focused on the global stage with a keen eye on the domestic market.

The global market for just the top 10 drug delivery technologies is headed for around $81.5B by 2015 and RBCC is working with TheraKine to tap that huge capital flow by seeking out new licenses for TheraKine’s portfolio of patented, selective, tunable, and site-specific drug delivery technologies abroad (reported April 24). There are a bounty of overseas healthcare providers just waiting to be harvested by such an advanced sustained-release delivery platform and the addition of new licenses is the best way for RBCC to keep the TheraKine partnership vital.

For more information on Rainbow Coral Corp., visit

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) Takes Initial Steps to Acquire Tech Innovators in $142 Billion Drug Delivery Market

May 21, 2013

Today before the opening bell, Rainbow Coral announced that it has opened talks this week to potentially partner with an emerging innovator in the transdermal delivery sector. This move is part of the company’s drive to carve out a share of the $142 billion U.S. drug delivery market.

Transdermal patches are an increasingly popular drug delivery system that is being developed for everything from contraception to Parkinson’s disease. Transdermal drug delivery prevents many of the problems associated with oral and intravenous routes as well as offers major advantages such as improved bioavailability, more uniform plasma levels, longer duration of action, reduced side effects, and improved therapy.

Some analysts have predicted that the transdermal delivery market could be worth as much as $31.5 billion by 2015 from a value of $21.5 billion just three years ago. Rainbow Coral believes partnering with an emerging leader in the sector could help the company capture a big piece of that growth.

“Transdermal patches offer a non-invasive option for treating many diseases and disorders,” said RBCC CEO Patrick Brown. “The appeal is obvious. We’re in negotiations now with a patch developer we believe has high profit potential, and we’re optimistic that a deal can be struck soon.”

For more information, visit

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) Partner Nano3D Inks Distribution Deal to Send Breakthrough Cellular Technology to Market

May 13, 2013

Rainbow Coral, via wholly owned subsidiary Rainbow BioSciences LLC, seeks out new partnerships with biotechnology developers to deliver new medical technologies and innovations to market. The company today reported that one such partner, Nano3D Biosciences (n3D), is positioned to commercialize its BioAssembler product line in the U.S. marketplace through a distribution agreement with St. Louis-based scientific products distributor, MIDSCI.

The BioAssembler is a breakthrough technology that allows researchers to culture cells in three dimensions, creating lifelike tissues similar to those found naturally within the body. Per the agreement, MIDSCI will market and sell BioAssembler technology to life sciences researchers in pharmaceutical, biotech, academic, and government laboratories across the nation.

“With MIDSCI’s focus on the cell culture market in the U.S. and the capabilities of its sales and marketing organization in addressing the needs of the life science researchers in a variety of market segments, this distribution partnership will provide even easier access to our 3D cell culture (technology) for researchers in the U.S.,” n3D president and CSO Dr. Glauco Souza stated in the press release.

RBCC last year signed a joint-venture agreement with n3D to assist in the development and market the BioAssembler. The company notes heightened interest in n3D’s magnetic levitation technology after it was featured in an article in Nature, the world’s premiere science journal, and says the new distribution deal will establish even greater visibility.

“This deal with MIDSCI is a major step forward in turning this revolutionary technology into the global standard in cellular research,” said RBCC CEO Patrick Brown.

For more information visit

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) Partner Touted by World’s Premiere Science Journal

May 6, 2013

Nature, the world’s premiere science journal, seems to finally understand what Rainbow Coral Corp. has known for some time: The cell-growth technology pioneered by RBCC partner n3D Biosciences has the potential to completely revolutionize cellular research.

n3D’s magnetic levitation technology was the subject of a feature article in the journal’s April issue titled “A Better Brew.” The system allows researchers at university laboratories and pharmaceutical companies to grow three-dimensional, lifelike microtissues similar enough to those found within the body to be used in in vivo drug-testing models. RBCC signed a joint venture agreement to help market and develop the technology last year.

The abstract of the article is available now at n3D’s website

According to RBCC CEO Patrick Brown, the high-profile feature is certain to spread the word on n3D’s groundbreaking magnetic levitation system to labs across the globe at a time when researchers are eagerly adopting and evaluating 3D cell-growth formats.

“We strongly believe that n3D’s levitation technology is the future of cellular research,” Brown emphasized. “We anticipate an explosion of interest in the company and its products as a result of this terrific Nature article.”

Rainbow BioSciences, RBCC’s biotech division, signed a joint venture agreement with n3D last year to help develop and market the Bio-Assembler. For more information on this and other biotech initiatives, visit

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) Prepares for Revolution in Pharmaceutical and Insurance Industries

April 30, 2013

The rapid growth of personalized genomic medicine is poised to radically change not only the way that pharmaceutical companies develop drugs, but the way insurance companies administer healthcare plans. Acknowledging the increasing momentum, Rainbow Coral today told investors that it is forging ahead with plans for new partnerships in both genetic testing and companion diagnostics.

PricewaterhouseCoopers predicts that the personalized medicine sector could grow to as much as $452 billion by 2015. One of the driving forces behind this expansion is the inefficient way in which drugs are currently produced. Because insurance companies try to avoid paying for drugs that don’t work, pharmaceutical companies are beginning to use data derived from personalized genome testing to indicate which drugs will work for specific patients—making a stronger case for payer reimbursement.

In March, MedCity News reported that over half of pharmaceutical giant AstraZeneca’s drug pipeline is being developed as personalized medicine. RBCC believes that percentage will continue to rise as insurance companies begin to mandate genetic testing for patients before agreeing to pay for new prescriptions.

“It changes the business model completely,” emphasized RBCC CEO Patrick Brown. “Personalized medicine, including genetic testing and companion diagnostics, is already helping to develop pharmaceuticals personalized to patients. Soon, their healthcare plans will be personalized, too.”

In order to secure a growing share of a personalized medicine market that is becoming increasingly lucrative, the company is seeking out new innovations and technologies that promise to dramatically improve patient outcomes and reduce healthcare costs. For more information on Rainbow BioSciences’ personalized medicine initiatives, visit

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) Takes International Approach to Finding Potentially Lucrative Licensing Opportunities

April 24, 2013

In the goal of increasing market opportunities for its biotech innovations, Rainbow Coral is now looking for new overseas targets that could benefit from adding licenses for the drug delivery protocols that its joint venture partner, TheraKine, has developed.

According to some experts, the worldwide market for the 10 most popular drug delivery technologies (DDTs) alone could grow to $81.5 billion by 2015. TheraKine is a leader in this space, having developed and patented novel, tunable technologies with the potential to enable selective, site-specific drug delivery. These technologies promise to lower drug concentrations and significantly reduced risk of drug toxicity.

Focused on building market share in this fast-growing sector, RBCC is targeting overseas healthcare providers for whom TheraKine’s advanced sustained-release delivery system could yield significant returns for their clients.

“Licensing is the key to making this a successful partnership with TheraKine,” said RBCC CEO Patrick Brown. “Together, we can spread this revolutionary technology around the globe to the doctors and patients who need it most.”

For more information on Rainbow BioSciences’ personalized medicine initiatives, please visit

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) and the New World of Pharmacogenomics

April 22, 2013

Immunotherapy and stem cell technology represent two of the hottest fields in medical science today. Although there is still much research to be done, immunotherapy is seen as the ultimate weapon against some of the most intractable diseases, essentially having the best potential to hunt out and destroy bad cells. And stem cell technology is seen as the best hope for regenerating the body, essentially building more good cells.

But there’s a third less known but no less important component to the future of modern medicine. It’s called pharmacogenomics, a field of study derived from the Human Genome Project. The goal of pharmacogenomics is to provide doctors and researchers the tools necessary to accurately assess genetic variations in patients, and eventually provide drug treatment options that are finely tuned to each patient’s needs, avoiding the trial-and-error approach that doctors are so often forced to rely on. It’s a critical science that could greatly leverage other medical technologies.

Differences in how drugs are metabolized, and their ultimate effects, frequently have a genetic base, and knowing a patient’s genetic makeup could mean the difference between a treatment’s success and failure. When Rainbow Coral Corp. recently announced its plan to partner with a genome-mapping facility in Houston, they were targeting one of the fastest growing segments in biotech, the genetic testing sector, expected to reach $2.2 billion by 2017.

It’s just one of the company’s moves to implement its strategy of developing the best research and drug therapy products. Rainbow also recently acquired a new equity interest in Nano3D Biosciences, an emerging biotech game-changer, whose Bio-Assembler technology may soon allow researchers to dramatically shorten the development timeline for new drugs and treatments, an area that has the potential for explosive growth.

For additional information, visit

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) Subsidiary’s Negotiations with Leading Genetic Testing Lab Nearly Complete

April 15, 2013

Rainbow BioSciences, the biotech division of Rainbow Coral, this morning told investors that it is nearing a definitive agreement with a leading, Texas-based genetic testing laboratory.

One of the fastest-growing segments of the global biotech industry, the genetic testing sector is projected to reach $2.2 billion by 2017. The laboratory in negotiations with RBCC specializes in the cutting-edge science of pharmacogenomics, a field of study resulting from the Human Genome Project that seeks to help doctors assess genetic variations in patients in order to create more effective, optimized drug treatment plans.

Pharmacogenomics could be the key to truly personalized medicine, which RBCC views as the future of healthcare. For more information on Rainbow BioSciences’ personalized medicine initiatives, visit

While continually seeking out new partnerships with biotechnology developers, Rainbow BioSciences is focused on developing new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT), and Amgen Inc. (NASDAQ: AMGN).

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) Expands Focus in Booming $232 Billion Personalized Medicine Market

April 8, 2013

Today before the opening bell, Rainbow Coral announced that its biotech subsidiary, Rainbow BioSciences, will be targeting new innovations in the growing field of companion diagnostics.

Ripe for expansion, the U.S. personalized medicine market is expected to grow to as much as $452 billion by 2015. Companion diagnostics is one of the fastest-growing fields in the market; it alone could total $42 billion in size by 2015, according to industry analysts

The key to ongoing rapid growth will be innovation. Companion diagnostics is the use of genetic variation to chart different patient responses to specific drugs or biologic agents in order to create effective, efficient treatments tailored to a patient’s genetic profile. Many experts believe the emerging field will have an increasingly important role to play in cancer treatments in coming years.

“Companion diagnostics represent the very cutting edge of technology in medicine today,” said RBCC CEO Patrick Brown. “We believe the key to our success is bringing desperately needed new innovations to the market that will improve patient outcomes and reduce healthcare costs. Companion diagnostics offer us the best opportunities to achieve that goal.”

For more information on Rainbow BioSciences’ personalized medicine initiatives, please visit

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) Launches New Website, Highlights Impressive Deal Flow

April 2, 2013

Last week, Rainbow BioSciences, the biotechnology division of Rainbow Coral Corp., revealed a new website highlighting its explorations into the multi-billion-dollar drug delivery and genome-mapping market. The new website replaces the prior version and can be found at

The revamped site details the company’s new partnership with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective, and more convenient than ever before. Some experts believe that the worldwide market for the 10 most popular drug delivery technologies (DDTs) alone could grow to $81.5 billion by 2015.

RBCC also told investors that it is close to partnering with a cutting-edge genome-mapping facility in Houston capable of helping doctors assess genetic variations in patients in order to create more effective, optimized drug treatment plans. The genetic testing sector is one of the fastest-growing segments of the global biotech industry, with some market experts expecting it to reach $2.2 billion by 2017.

“The partnerships that we’re targeting could help usher in a new era of healthcare: personalized medicine,” said RBCC CEO Patrick Brown. “We see big growth in store for this sector, and Rainbow BioSciences’ improved website will help us keep shareholders, potential investors and other interested parties up to date on our latest activities to bring these revolutionary technologies to a pharmacy or clinic near you.”

Let us hear your thoughts: Rainbow Coral Corp. Message Board

Rainbow Coral Corp. (RBCC) Signs JV Agreement with Cutting-Edge Drug Delivery Company

March 20, 2013

Today before the opening bell, the biotech division of Rainbow Coral announced it has formed a Joint Venture (JV) with TheraKine to solve the problems presented by systemic drug delivery. The new JV is an extension of the company’s bold expansion into the $60 billion global drug delivery market.

TheraKine is the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective, and more convenient than ever before. The company has developed and patented these novel, tunable technologies with the potential to enable selective, site-specific drug delivery, allowing for lower drug concentrations and significantly reducing the risk of drug toxicity.

According to today’s release, this new sustained-release technology can also extend the patent life cycles of drugs. Offering pharmaceutical and biotech companies extended patent protection represents a tremendous market advantage and opportunity to increase profitability of FDA-approved drugs.

“TheraKine’s sustained-release delivery system could allow patients who now need daily injections to instead have one injection every four to six months,” stated RBCC CEO Patrick Brown. “We expect the demand for this product to be very high once it’s made available, and RBCC plans to take a real stake in its success.”

Stan Yakatan, TheraKine’s CEO, commented, “TheraKine is excited about the opportunity to partner with Rainbow to repurpose drugs with our sustained release technologies.”

For more information, visit

Let us hear your thoughts: Rainbow Coral Corp. Message Board


Select A Month
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Search


    Select A Category
  • 21st Century Holding Company TCHC (1)
  • 5BARz International Inc. BARZ (12)
  • 5G Wireless Communications Inc. FGWC (8)
  • 92 Resources Corp. RGDCF (15)
  • A.P. Pharma Inc. APPA (3)
  • Abazias Inc. ABZA (2)
  • ABcann Global Corp. ABCCF (29)
  • ABV Gold ABVG (11)
  • ACME Sports & Entertainment Inc. ASEN (2)
  • Adaptive Medias Inc. ADTM (6)
  • Advanced ID Corp. AIDO (5)
  • Advanced Medical Isotope Corp. ADMD (10)
  • Advanced Resources Group Ltd. AVRG (3)
  • Advanced Viral Research Corp. ADVR (9)
  • Advanced Visual Systems Inc. AVSC (10)
  • Advanced Voice Recognition Systems Inc. AVOI (11)
  • Advanced Wound Technologies Inc. AWTM (4)
  • Advaxis Inc. ADXS (2)
  • Agora Holdings Inc. AGHI (33)
  • Ahead of the Bulls (1)
  • AISystems, Inc. ASYI (11)
  • Aladdin Trading & Company ADTD (29)
  • Algae Dynamics Corp. ADYNF (31)
  • All American Gold Corp AAGC (13)
  • All Asia Licensing Inc. AASI (1)
  • ALL Fuels & Energy Company AFSE (49)
  • All Grade Mining Inc. HYII (3)
  • All Penny Stocks (3)
  • Allarae Healthcare Inc. ALHI (5)
  • Alliance Creative Group ACGX) (15)
  • Alliance Recovery Corp. ARVY (34)
  • Alltemp, Inc. LTMP (1)
  • APTD (2)
  • Alpine TLI Group Inc. APGR (7)
  • ALR Technologies Inc. ALRT (9)
  • Alternative Construction Technologies Inc. ACCY (10)
  • Alternative Energy Development Corp. ADEC (1)
  • Alternative Fuel Technology Inc. AFTC (1)
  • Alternet Systems Inc. ALYI (47)
  • AM Oil Resources & Technology Inc. AMOR (8)
  • Amarin Corp. AMRN (2)
  • Amaru Inc. AMRU (2)
  • Amerex Group, Inc AEXG (16)
  • American Capital Partners Inc. APRJ (1)
  • American Fiber Green Products Inc. AFBG (1)
  • American Oriental Bioengineering Inc. AOB (3)
  • American Racing Capital Inc. AMRA (2)
  • American Software (2)
  • Amgen Inc. AMGN (2)
  • AmMex Gold Mining Corp. AMXG (2)
  • Ampex Corp AMPX (1)
  • AnalytixInsight Inc. ATIXF (18)
  • Andover Medical Inc. ADOV (2)
  • Angstrom Microsystems Inc. AGMS (46)
  • Apolo Gold and Energy Inc. APLL (1)
  • Apple Inc. AAPL (13)
  • AppSwarm, Inc. SWRM (33)
  • Aquasil International Inc. AQUS (3)
  • Armco Metals Holdings Inc. AMCO (36)
  • AspenBio Pharma APPY (1)
  • Assured Pharmacy Inc. APHY (1)
  • Asta Funding Inc. ASFI (2)
  • Atlantic Energy Solutions Inc. AESO (1)
  • ATSI Communications Inc. ATSX (1)
  • Augme Technologies Inc. AUGT (70)
  • Auric Mining Corp. AUMY (3)
  • Automated Vending Technologies Inc. AVTC (3)
  • Automotive Company GNAU (11)
  • AV1 Group, Inc. AVOP (10)
  • Avalon Oil and Gas Inc. AOGN (16)
  • Avant Diagnostics Inc. AVDX (29)
  • Avatar Systems Inc. AVSY (3)
  • Axiom Management Inc. AXMA (3)
  • Axis Technologies Inc. AXTG (2)
  • B2Digital Inc. BTOD (18)
  • Balatia Airlines BLTA (2)
  • Bald Eagle Energy Inc. BEEI (18)
  • Banjo & Matilda Inc. BANJ (8)
  • (4)
  • Beacon Enterprise Solutions Group BEAC (47)
  • Beacon Equity Research (552)
  • Beijing Med-Pharm Corp. BGJP (2)
  • Bergamo Acquisition Corp. BGMO (15)
  • Big Tree Group Inc. BIGG (36)
  • Bio-Clean International Inc. BCLE (1)
  • Bio-Matrix Scientific Group Inc. BMSN (1)
  • BioCentric Energy Holdings Inc. BEHL (1)
  • Biomagnetics Diagnostics Corp. BMGP (3)
  • bioMETRX Inc. BMRX (1)
  • Bionic Products Corp. BNPD (4)
  • Biophan Technologies Inc. BIPH (1)
  • BioSolar Inc. BSRC (22)
  • Biotech Holdings Ltd. BIOHF (3)
  • Inc. BZRT (9)
  • Black Diamond Brands Corp. BDMHF (1)
  • Blue Diamond Ventures Inc. BLDV (1)
  • Blue Moon Zinc Corp. BMOOF (8)
  • Blue Water Global Group Inc. BLUU (7)
  • Blugrass Energy Inc. BLUG (4)
  • Bollente Companies, Inc. BOLC (7)
  • (1)
  • Boreal Water Collection Inc. BRWC (23)
  • Boston Therapeutics Inc. BTHE (20)
  • Bridgetech Holdings International Inc. BGTH (1)
  • Brighton Oil & Gas Inc. BROG (8)
  • Britannia Mining Inc. BMIN (14)
  • Brite Strike Tactical Illumination Products, Inc. BSTI (41)
  • Brookside Technology Holdings Corp BKSD (2)
  • Bullzi Security Inc. BLLZ (3)
  • BWI Holdings Inc. BWIH (165)
  • Cache Elite Inc. ILUS (10)
  • Cal-Bay International Inc. CBYI (6)
  • Callisto Pharmaceuticals, Inc. (1)
  • Calpian Inc. CLPI (27)
  • CAMAC Energy Inc. CAK (2)
  • Canam Energy Inc. CNGJ (10)
  • CanAm Uranium Corp. CAUI (58)
  • Cannabics Pharmaceuticals Inc. CNBX (14)
  • Capital City Energy Group Inc. CETG (18)
  • Car Monkeys Group CKMY (15)
  • Carbon Sciences Inc. CABN (21)
  • CardioVascular BioTherapeutics Inc. CVBT (5)
  • Cardium Therapeutics Inc. CXM (44)
  • Carl Data Solutions Inc. CDTAF (5)
  • Cascade Technologies Inc. CSDT (2)
  • Cascadia Investment Inc. CDIN (4)
  • Casey Corp. CCPR (1)
  • Cashcow Magazine (4)
  • Cavico Corp. CVIC (3)
  • CD International Enterprises, Inc. CDII (48)
  • CDC Corp. CHINA (4)
  • CelebDirect Inc. CELI (3)
  • Cellceutix Corp. CTIX (18)
  • CellCyte Genetics Corp. CCYG (3)
  • Century Group, Inc. CEYG (1)
  • CEOcast (184)
  • CepTor Corp. CEPO (1)
  • Cereplast Inc. CERP (9)
  • Chancery Resources Inc. CCRY (3)
  • Changing Times Vitamins Inc. SGTB (12)
  • CHDT Corp. CHDO (5)
  • Cherubim Interests Inc. CHIT (36)
  • China 3C Group CHCG (13)
  • China America Holdings Inc. CAAH (8)
  • China Direct Inc. CDS (4)
  • China Education Alliance Inc. CEUA (4)
  • China Energy Recovery Inc. CGYV (12)
  • China Growth Development Inc. CGDI (2)
  • China Health Management Corp CNHC (7)
  • China Health Resource Inc. CHRI (14)
  • China INSOnline Corp. CHIO (1)
  • China Jiangsu Golden Horse Steel Ball Inc. CJGH (3)
  • China Logistics Group Inc. CHLO (11)
  • China Media Group Corp. CHMD (2)
  • China Medicine Corporation CHME (5)
  • China Nuvo Solar Energy Inc. CNUV (3)
  • China Organic Agriculture Inc. CNOA (11)
  • China Petroleum and Chemical Corp. SNP (2)
  • China Voice Holding Corp. CHVC (47)
  • China Wind Systems Inc. CWSI (6)
  • China Wireless Communications Inc. CWLC (4)
  • China Yongxin Pharmaceuticals Inc. CYXN (5)
  • China YouTV Corp. CYTV (1)
  • ChinaTel Group Inc. CHTL (1)
  •, Inc. CIIX (111)
  • Choom Holdings Inc. CHOOF (12)
  • ChromaDex Corp. CDXC (3)
  • City Capital Corp. CTCC (2)
  • Cityside Tickets CIST (21)
  • CleanTech BioFuels Inc. CLTH (10)
  • Cleantech Transit Inc. CLNO (3)
  • Clearly Canadian Beverage Corp. CCBEF (13)
  • Cleartronic Inc. CLRI (52)
  • Clenergen Corp. CRGE (37)
  • CMG Holdings Inc. CMGO (2)
  • Coastal Integrated Services Inc. COLV (13)
  • Coil Tubing Technology Inc. CTBG (1)
  • Colorado Goldfields Inc. CGFI (5)
  • Colt Resources Inc. COLTF (13)
  • Columbia River Resources Inc. CRVR (1)
  • CoMedia Corp. CMTN (1)
  • CommercePlanet Inc. CPNE (4)
  • Compress Technologies Inc. CTLG (17)
  • Conforce International Inc. CFRI (2)
  • CAJT (9)
  • Cono Italiano Inc. CNOZ (12)
  • Consorteum Holdings, Inc. CSRH (171)
  • Consorteum Holdings, Inc. CSRH (4)
  • ContentChecked Holdings Inc. CNCK (60)
  • Continental Fuels Inc. CFUL (2)
  • Converde Energy USA Inc. XFUL (12)
  • Convergence Technology Group Inc. CNVC (7)
  • Copper King Mining Corp. CPRK (2)
  • Cord Blood America Inc. CBAI (102)
  • Crdentia Corp CRDT (12)
  • Creative Vistas Inc. CVAS (2)
  • Crystal International Travel Group Inc. CINT (4)
  • Cubic Energy Inc. QBC (2)
  • Cybermesh International Corp. CYTL (1)
  • Cyclone Power Technologies Inc. CYPW (9)
  • CYIOS Corp. CYIO (1)
  • Daily Views (13)
  • Dakshidin Corp. DKSC (5)
  • Data Call Technologies Inc. DCLT (25)
  • Daulton Capital Corp. DUCP (26)
  • Davi Skin Inc. DAVN (1)
  • Debt Resolve Inc. DRV (2)
  • Debut Broadcasting Corporation Inc. DBTB (1)
  • Deep Blue Marine Inc. DPBM (6)
  • Deep Down Inc. DPDW (15)
  • Deer Valley Corp. DVLY (2)
  • Defense Solutions Inc. DFSH (3)
  • Delta Mining and Exploration Corp. DMXC (1)
  • Dermisonics Inc. DMSI (1)
  • Destination Television Inc. DSTV (17)
  • Dhanoa Minerals Ltd. DHNA (4)
  • DigitalPost Interactive Inc. DGLP (8)
  • Document Capture Technologies Inc. DCMT (3)
  • DoMark International Inc. DOMK (29)
  • Dominovas Energy Corp. DNRG (73)
  • Dragon Capital Group Corp. DRGV (11)
  • Dragon International Group Corp. DRGG (2)
  • Duma Energy Corp. DUMA (20)
  • Duska Therapeutics Inc. DSKA (1)
  • Dutton Associates (88)
  • DXP Enterprises Inc. DXPE (4)
  • Dynamic Media Holdings Inc. DYMH (6)
  • Dynamic Response Group Inc. DRGP (6)
  • Dynasty Limousine Inc. DNYS (19)
  • Earth Dragon Resources Inc. EARH (10)
  • Eastbridge Investment Group Corp. EBIG (1)
  • Ebenefits Direct, Inc. EBFD (21)
  • eCareer Holdings Inc. ECHI (9)
  • Echo Therapeutics Inc. ECTE (5)
  • EcoloCap Solutions Inc. ECOS (2)
  • Ecologic Transportation Inc. EGCT (11)
  • Ecosciences Inc. ECEZ (1)
  • Ecotality, Inc. ECTY (67)
  • eCrypt Technologies Inc. ECRY (79)
  • EdgeTech International Inc. EGIL (6)
  • eDoorways Corp. EDWY (183)
  • Inc. EFSF (4)
  • EFuel EFN Corp. EFUL (1)
  • EGPI Firecreek Inc. EFIR (1)
  • Elephant Talk Communications Corp. ETAK (8)
  • Elephant Talk Communications Inc. ETAK (2)
  • Elleipsis Global Travel Solutions Inc. EGTS (3)
  • Elray Resources Inc. ELRA (11)
  • Elron Electronic Industries Ltd. ELRN (1)
  • Emerging Media Holdings Inc. EMDH (22)
  • Empire Energy Corporation International EEGC (3)
  • Endeavor Explorations Inc. EAVR (7)
  • Endeavour Silver Corp. EXK (3)
  • Endevco Inc. EDVC (2)
  • Energtek Inc. EGTK (61)
  • Enherent Corp. ENHT (2)
  • EnterConnect Inc. ECNI (5)
  • Enterprise Oilfield Group Inc. E.TO (13)
  • EnXnet Inc. EXNT (1)
  • Epazz, Inc. EPAZ (48)
  • Equity Stock Analysis (1)
  • ER Urgent Care Holdings Inc. ERUC (6)
  • ERF Wireless Inc. ERFB (15)
  • Essential Innovations Technology Corp. ESIV (2)
  • Inc. ETLC (3)
  • Ethema Health Corporation GRST (7)
  • Euoko Group Inc. EUOK (2)
  • EV Innovations Inc. EVII (189)
  • EV Transportation Inc. EVTP (7)
  • EVIO, Inc. EVIO (33)
  • Exchange Media Corp. EXMD (9)
  • Exeter Resource Corp. XRA (2)
  • eXp World Holdings, Inc. EXPI (81)
  • Expert Group Inc. EXPT (5)
  • ExpressIR Inc. (1)
  • Extreme Motorsports of California, Inc. EMOC (26)
  • ezBanc-A Stocklender's Journal (6)
  • Falcon Crest Energy FCEN (75)
  • Falcon Ridge Development Inc. FCNR (2)
  • Famous Uncle Als Hot Dogs & Grille Inc FDOG (10)
  • FANDOM SPORTS Media Corp. FDMSF (5)
  • Fastfunds Financial Corp. FFFC (17)
  • Financial Media Group, Inc. FNGP (26)
  • Financial Services Exchange FSE (1)
  • First Cobalt Corp. FTSSF (49)
  • First Titan Corp. FTTN (45)
  • FlexWeek Inc. FXWK (11)
  • FluoroPharma Medical Inc. FPMI (46)
  • Foldera, Inc. FDRA (11)
  • Force Energy Corp. FORC (5)
  • FormCap Corp. FRMC (29)
  • Fortune Market Media Inc. FTMM (5)
  • Franklin Mining Inc. FMNJ (1)
  • Freedom Leaf Inc. FRLF (12)
  • Fresh Harvest Products Inc. FRHV (7)
  • Fresh Promise Foods Inc. FPFI (12)
  • Freshstart Properties Inc. FSPP (1)
  • FrogAds Inc. FROG (6)
  • Frozen Food Gift Group Inc. FROZ (5)
  •, Inc. FNDM (56)
  • Fushi Copperweld Inc. FSIN (2)
  • GainClients Inc. GCLT (9)
  • Galenfeha Inc. GLFH (28)
  • Gastar Exploration Ltd. GST (2)
  • Gemini Explorations Inc. GXPI (12)
  • Gen2media Corp. GTWO (2)
  • General Environmental Management Inc. GEVI (56)
  • General Metals Inc. GNMT (1)
  • General Steel Holdings Inc. GSI (3)
  • GeoBio Energy Inc. GBOE (1)
  • GeoEye Inc. GEOY (4)
  • GeoPharma Inc GORX (1)
  • Giggles N’ Hugs Inc. GIGL (90)
  • Global Alumina Corp. GLA.U (1)
  • Global General Technologies Inc. GLGT (1)
  • Global Hemp Group, Inc. GBHPF (10)
  • Global Payout Inc. GOHE (109)
  • Global Realty Development Corp. GRLY (10)
  • Global Resource Corporation GBRC (48)
  • Global Roaming Distribution Inc. GRDB (34)
  • GlobalWise Investments Inc. GWIV (129)
  • GNCC Capital Inc. GNCP (24)
  • Golden West Brewing Company Inc. GWBC (3)
  • GoldSpring Inc. GSPG (4)
  • Google, Inc. GOOG (8)
  • (1)
  • Grandview Gold Inc. GVGDF (2)
  • Gray Publishing & Media, Inc. GPMIJ (15)
  • Graystone Park Enterprises Inc. GPKE (7)
  • Great Plains Holdings Inc. GTPH (28)
  • Green Earth Technologies GETG (1)
  • Green Star Alternative Energy Inc. GSAE (2)
  • Green Star Products Inc. GSPI (2)
  • Green Technology Solutions Inc. (GTSO) (19)
  • Greenbelt Resources Corp. GRCO (1)
  • Greenchek Technology Inc. GCHK (18)
  • Greenkraft, Inc. GKIT (22)
  • Greenstone Holdings Inc. GSHN (2)
  • Grey Cloak Tech, Inc. GRCK (24)
  • GRILLiT Inc. GRLT (8)
  • Growblox Sciences Inc. GBLX (24)
  • GT Legend Automotive Holdings Inc. GTLA (2)
  • GTX Corp GTXO (49)
  • Gulf Western Petroleum Corp. GWPC (3)
  • GWS Technologies Inc. GWSC (4)
  • Halcyon Jets Holdings Inc. HJHO (15)
  • Halitron Inc. HAON (11)
  • Hanover Financial Services (17)
  • Harbin Electric Inc. HRBN (2)
  • Harvey Electronics Inc. HRVE (1)
  • Hasco Medical Inc. HASC (7)
  • Hathway Corp. HWYI (1)
  • HeadsUp Entertainment International Inc. HDUP (3)
  • Healthnostics Inc. HNSO (1)
  • HealthSonix Inc. HSXI (1)
  • HealthSport Inc. HSPO (14)
  • Heartland Inc. HTLG (1)
  • Heartland Oil and Gas Corp. HTOG (7)
  • Hemis Corporation HMSO (19)
  • Hemisphere Gold Inc. HPGI (1)
  • Hemp Inc. HEMP (25)
  • Hendrx Corp. HDRX (1)
  • Hi-Shear Technology Corp. HSR (3)
  • HighCom Global Security Inc. HCGS (19)
  • HII Technologies Inc. HIIT (8)
  • Holloman Energy Corp. HENC (2)
  • Holmes Osborne (6)
  • Hologic Inc. HOLX (4)
  • Home Shopping Latino Inc. HSPG (8)
  • Hong Kong Highpower Technology Inc. HPJ (2)
  • HotOTC (61)
  • HotStockChat (3)
  • HotStockMarket (HSM) (3)
  • HST Global Inc. HSTC (11)
  • Hunt Gold Corp. HGLC (32)
  • HWI Global Inc. HWIC (3)
  • Hydrogen Corp. HYDG (1)
  • i-Level Media Group Inc. ILVL (3)
  • i2 Telecom International Inc. ITUI (7)
  • iB3 Networks Inc. IBNW (1)
  • IceWEB Inc. IWEB (5)
  • ICP Solar Technologies Inc. ICPR (3)
  • IDGLOBAL Corp. IDGJ (2)
  • IDO Security Inc. IDOI (22)
  • IEG Holdings Corp. IEGH (22)
  • IFAN Financial Inc. IFAN (34)
  • iGambit, Inc. IGMB (5)
  • Imaging3 Inc. IMGG (2)
  • ImaRx Therapeutics Inc. IMRX (2)
  • Immune Therapeutics Inc. IMUN (11)
  • Impact E-Solutions Corp. IESO (1)
  • Imperial Petroleum Inc. IPMN (10)
  • Inca Designs Inc. IDGI.PK (4)
  • Independent Film Development Corp. IFLM (1)
  • Index Oil and Gas Inc. IXOG.OB (5)
  • India Globalization Capital, Inc. IGC (21)
  • Industrial Biotechnology Corp. IBOT (1)
  • Infinite Group Inc. IMCI (48)
  • Inform Worldwide Holdings, Inc. IWWI (27)
  • InMed Pharmaceuticals, Inc. IMLFF (38)
  • Intec LTD ICLJY (1)
  • IntegraMed America Inc INMD (1)
  • Intelecom Inc. IECM (3)
  • Intelimax Media Inc. IXMD (31)
  • Intelligent Highway Solutions Inc. IHSI (6)
  • Intercept Energy Services Inc. IESCF (7)
  • Interleukin Genetics Inc. ILI (1)
  • International Barrier Technology Inc IBTGF (1)
  • International Consolidated Companies Inc. INCC (2)
  • International Stem Cell Corp. ISCO (226)
  • Inventergy Global Inc. INVT (15)
  • Investor Village (9)
  • Investors Business Daily (4)
  • InvestorsProfs (1)
  • InvestSource (11)
  • IPOs (8)
  • IR Biosciences Holdings Inc IRBS (3)
  • Isonics Corp. ISON (1)
  • ItsAboutFinance (2)
  • JC Data Solutions Inc. JCDS (4)
  • Joytoto USA Inc. JYTO (14)
  • JZZ Technologies Inc. JZZI (3)
  • KAL Energy Inc. KALG (3)
  • Kallo Inc. KALO (43)
  • Kandi Technologies Corp. KNDI (3)
  • KCM Holding Corp. KCMH (3)
  • Kingslake Energy Inc. KGLJ (2)
  • Klondex Mines Ltd. KLNDF (1)
  • Knobias KNBS (5)
  • Kootenay Zinc Corp. KTNNF (12)
  • Kraig Biocraft Laboratories Inc. KBLB (88)
  • L&L International Holdings Inc. LLFH (2)
  • Laguna Blends Inc. LAGBF (53)
  • Lantis Laser Inc. LLSR (5)
  • Last Mile Logistics Group LMLG (4)
  • Latitude 360 Inc. LATX (21)
  • LD Holdings Inc. LDHL (14)
  • Legacy Holdings Inc. LGYH (1)
  • Legacy Ventures International Inc. LGYV (24)
  • Legend Media Inc. LEGE (4)
  • Lexaria Bioscience Corp. LXRP (74)
  • Liberty Leaf Holdings Ltd. LIBFF (10)
  • Lifespan Inc. LSPN (1)
  • Lime Energy Corp. LIME (3)
  • Lingo Media Corp. LMDCF (18)
  • Linkwell Corporation LWLL (4)
  • Liquor Group Wholesale Inc. LIQR (22)
  • Inc. LFLS (47)
  • LOGIC Devices Inc. LOGC (1)
  • Logility Inc. LGTY (1)
  • LoJack Corp LOJN (3)
  • Longhai Steel Inc. LGHS (10)
  • LottoGopher Holdings Inc. LTTGF (26)
  • Lotus Pharmaceuticals Inc. LTUS (1)
  • Low Carbon Technologies (LWCTF) (3)
  • Lucas Energy, Inc. LEI (17)
  • Mabwe Minerals Inc. MBMI (56)
  • Macquarie Infrastructure Company MIC (5)
  • Maine and Maritime Corp. MMA (1)
  • Majic Wheels Corp. MJWL (6)
  • Makeup Inc. MAKU (2)
  • Mammoth Energy Group Inc. MMTE (5)
  • Mantra Venture Group Ltd. MVTG (10)
  • Marijuana Company of America, Inc. MCOA (37)
  • Mariner’s Choice International Inc. MCII (2)
  • Martin Nutraceuticals MNIU (11)
  • Material Technologies Inc. MTCH (44)
  • Max Media Group Inc. MXMI (9)
  • Max Sound Corp. MAXD (30)
  • MC Endeavors Inc. MSMY (2)
  • MedeFile International Inc. MDFI (46)
  • MediaG3 Inc. MDGC (1)
  • Medical Cannabis Payment Solutions (REFG) (13)
  • Medical Cannabis Payment Solutions REFG (19)
  • Medical Innovation Holdings, Inc. MIHI (16)
  • Medical Transcription Billing Corp. MTBC (13)
  • Medina International Holdings Inc. MIHI (3)
  • Medisafe 1 Technologies Corp. MFTH (3)
  • Medivisor Inc. MVSR (1)
  • Mega Media Group, Inc. MMDA (30)
  • MegaWest Energy Corporation MGWSF (2)
  • Memry Corp. MRY (2)
  • Metro One Development Inc. MODI (2)
  • Mexico Energy Corp. MXC (1)
  • MGX Minerals, Inc. MGXMF (52)
  • Micro Identification Technologies Inc. MMTC (44)
  • MicrocapMoney (2)
  • Microsoft Corporation MSFT (4)
  • Midway Gold Corp. MDW (1)
  • Military Resale Group MYRL (19)
  • Minco Silver Corp. MSV.TO (1)
  • Mindpix Corp. MNDP (1)
  • MIP Solutions Inc. MSOL (7)
  • MIT Holding MITD (36)
  • MitoPharm Corp. MTPH (1)
  • Mizati Luxury Alloy Wheels, Inc. MZTI (14)
  • Mobile Entertainment Inc. MBEI (1)
  • Mobile Lads Corp. MOBO (43)
  • Momentous Entertainment Group Inc. MMEG (19)
  • Monaker Group Inc. MKGI (48)
  • Money4Gold Holdings Inc. MFGD (3)
  • Holdings Inc. MBKR (2)
  • Mosquito Consolidated Gold Mines Limited MSQ.V (1)
  • Moxian Inc. MOXC (62)
  • mPhase Technologies Inc. XDSL (12)
  • MSE Enviro-Tech Corp. MEVT (4)
  • Muscle Flex Inc. MFLI (55)
  • MusclePharm Corp. MSLP (23)
  • Mvive Inc. MVIV (22)
  • My Automated Advisor (4)
  • MyECheck Inc. MYEC (99)
  • Inc. MYST (1)
  • Nanogen Inc. NGEN (2)
  • Nanometrics Inc. NANO (1)
  • NanoSensors Inc. NNSR (1)
  • NanoTech Entertainment Inc. NTEK (30)
  • Napster, Inc. NAPS (5)
  • National Automation Services Inc. NASV (67)
  • National Coal Corp. NCOC (2)
  • National Waste Management Holdings Inc. NWMH (24)
  • Naturally Iowa Inc. NLIA (2)
  • NavStar Technologies Inc. NVSR (16)
  • nCoat Inc NCOA (8)
  • Neah Power Systems NPWZ (14)
  • Neohydro Technologies Corp. NHYT (4)
  • Neoprobe Corp. NEOP (6)
  • NeoStem Inc. NBS (6)
  • Net Element Inc. NETE (19)
  • NetSol Technologies Inc NTWK (64)
  • Neurobiological Technologies Inc. NTII (3)
  • NeuroMama Ltd. NERO (15)
  • Neutra Corp. NTRR (37)
  • New Asia Gold Corp. NWAG (1)
  • New Generation Biofuel Holdings Inc. GNB (3)
  • NewMarket China Inc. NMCH (7)
  • NewMarket Technology Inc. NMKT (7)
  • Newport Digital Technologies Inc. NPDT (61)
  • Nexia Holdings Inc. NXHD (51)
  • NexMed Inc. NEXM (8)
  • NeXplore Corp. NXPC (4)
  • Next One Interactive Inc. NXOI (7)
  • NextGen Bioscience Inc. NXGB (1)
  • NextPhase Wireless Inc. NPHS (1)
  • Nexus Enterprise Solutions Inc. NXES (30)
  • NF Energy Saving Corp. of America NFES (1)
  • Nhale Inc. NHLE (18)
  • Nilam Resources Inc. NILR (4)
  • Nitro Petroleum Inc. NTRO (5)
  • North Bay Resources Inc. NBRI (10)
  • NuTech Inc. NTCI (1)
  • Nutra Pharma Corp. NPHC (21)
  • NutraNomics Inc. NNRX (30)
  • NuVim Inc. NUVM (1)
  • NVIDIA Corp. NVDA (1)
  • NXGen Holdings Inc. NXGH (1)
  • Oakridge Global Energy Solutions Inc. OGES (63)
  • Obee's Franchise Systems Inc. OBFM (1)
  • OBJ Enterprises Inc. OBJE (27)
  • Odyne Corporation ODYC (15)
  • Omega Commercial Finance Corp. OCFN (2)
  • OmniaLuo Inc. OLUO (1)
  • Omnicity Corp. OMCY (26)
  • Omninet Media.Com, Inc. ONMC (5)
  • On The Go Healthcare Inc. MODI (13)
  • On the Move Systems Inc. OMVS (102)
  • Oncolin Therapeutics Inc. OCOL (1)
  • One Step Vending Corp. KOSK (2)
  • One World Holdings Inc. OWOO (61)
  • Ones to Watch (1,353)
  • Onstream Media Corp. ONSM (5)
  • Onteco Corp. ONTC (4)
  • Open Energy Corp. OEGY (4)
  • Optical Systems Inc. OPSY (2)
  • Oramed Pharmaceuticals Inc. ORMP (2)
  • Organic Alliance Inc. ORGC (2)
  • ORHub, Inc. ORHB (32)
  • (82)
  • OtcStockExchange (5)
  • OurPet's Company OPCO (78)
  • OxySure Systems Inc. OXYS (23)
  • P2 Solar Inc. PTOS (24)
  • Pacific Gold Corp. PCFG (3)
  • Pamplona Picks (1)
  • Pan Global Corp. PGLO (82)
  • PanGenex Corp. PGCX (3)
  • Paramount Gold and Silver Corp. PZG (3)
  • Patient Access Solutions Inc. PASO (7)
  • Patriot Energy Corp. dba TelTeck Solutions Inc PGYC.PK (11)
  • Patriot One Technologies, Inc. PTOTF (25)
  • Patriot Scientific Corp. PTSC (6)
  • Peace Arch Entertainment Group Inc. PAE (1)
  • Peoples Educational Holdings Inc. PEDH (2)
  • Perf Go Green Holdings Inc. PGOG (12)
  • Perfect Web Technologies, Inc PWBI (11)
  • Perfectenergy International Ltd. PFGY (1)
  • Performance Health Technologies Inc. PFMH (31)
  • Pet DRX Corp. VETS (1)
  • Petro Resources Corp. PRC (2)
  • Petrogress, Inc. PGAS (27)
  • PetroSun Inc. PSUD (41)
  • Petroteq Energy Inc. PQEFF (50)
  • Phantom Fiber Corp. PHFB (2)
  • Pilot Financial Communications (3)
  • Pipex Pharmaceuticals Inc. PP (2)
  • PITOOEY! Inc. PTOO (14)
  • Pivot Pharmaceuticals Inc. PVOTF (1)
  • Planet Nutrition Inc. PNHL (4)
  • Platina Energy Group Inc. PLTG (8)
  • PlayBOX Inc. PYBX (5)
  • Players Network PNTV (15)
  • Pluristem Therapeutics Inc. PSTI (10)
  • Positron Corp. POSC (3)
  • PotNetwork Holding, Inc. POTN (59)
  • Power of the Dream Ventures (1)
  • Power Play Development Corp. PWPY (17)
  • Powersafe Technology Corp. PWSF (1)
  • Premier Energy Corp. PNRC (1)
  • Pressure BioSciences Inc. PBIO (41)
  • PreveCeutical Medical Inc. PRVCF (22)
  • PRG Group Inc. PRGJ (2)
  • PrimEdge Inc. PEDI (1)
  • Private Equity Securities (93)
  • Pro Motors Group Corp. PMGU (2)
  • Pro Travel Network Inc. PTVL (2)
  • ProBility Media Corp. PBYA (33)
  • ProGaming Platforms Corp. PPTF (22)
  • Proginet Corp. PRGF (3)
  • Prom Resources PRMO (9)
  • Propalms Inc. PRPM (3)
  • Provectus Pharmaceuticals Inc. PVCT (12)
  • Puget Technologies Inc. PUGE (23)
  • Pulmo BioTech Inc. PLMO (4)
  • Puramed Bioscience Inc. PMBS (3)
  • Pure Biofuels Corp. PBOF (4)
  • Pure H2O Inc. PURH (1)
  • Pure Hospitality Solutions Inc. PNOW (99)
  • Purio Inc. PURO (5)
  • Puritan Financial Group Inc. PTNG (1)
  • Purple Beverage Company Inc. PPBV (8)
  • QED Connect Inc. QEDC (4)
  • Qiao Xing Universal Telephone Inc. XING (2)
  • QPC Lasers Inc. QPCI (3)
  • Qualcomm Inc. QCOM (2)
  • QualityStocks for Women (16)
  • QualityStocks Partner StockGuru (3,878)
  • QualityStocks Stock Newsletter (551)
  • QualityStocks Stock Newsletters (18,172)
  • QualityStocks Video Charts (286)
  • Market Basics (6)
  • QualityStocksNewsBreaks (839)
  • Quantum Fuel Systems Technologies Worldwide Inc. QTWW (15)
  • Quantum International Corp. QUAN (3)
  • Quasar Aerospace Industries Inc. QASP (6)
  • QuoteMedia Inc. QMCI (120)
  • Rafarma Pharmaceuticals Inc. RAFA (31)
  • Rainbow Coral Corp. RBCC (33)
  • Rancher Energy Corp. RNCH (9)
  • Raptor Resources Holdings Inc. RRHI (50)
  • Raven Gold Corp. RVNG (3)
  • Red Lake Exploration Inc. RLKX (19)
  • RegalWorks Media Inc. RWMI (4)
  • Regenicin, Inc. RGIN (6)
  • Reign Sapphire Corp. RGNP (13)
  • Reliant Financial Services Inc. RFNS (1)
  • Renhuang Pharmaceuticals Inc. RHGP (3)
  • ReoStar Energy Corp. REOS (1)
  • Resort Savers Inc. (RSSV) (10)
  • Revett Minerals (1)
  • RJD Green Inc. RJDG (19)
  • Rock Energy Resources Inc. RCKE (4)
  • Rodman & Renshaw (432)
  • Ronn Motor Company Inc. RNNM (6)
  • Rox Resources Ltd. RXRS (3)
  • Royal Quantum Group, Inc. RYQG (10)
  • Royal Standard Minerals Inc. RYSMF (2)
  • Rudy Nutrition RUNU (27)
  • RXi Pharmaceuticals Corp. RXII (3)
  • Santa Fe Gold Corp. SFEG (5)
  • Santa Fe Holding Company SFHD (3)
  • Save The World Air Inc. ZERO (12)
  • Savoy Energy Corp. SNVP (26)
  • SavWatt USA, Inc. SAVW (5)
  • Seabridge Gold Inc. SA (1)
  • Seawright Holdings Inc. SWRI (1)
  • Sector 10 Inc. SECI (78)
  • SES Solar Inc. SESI (2)
  • Seven Arts Pictures plc SAPX (1)
  • Seven Arts Pictures PLC SAPXF (5)
  • Shazam Stocks (22)
  • ShotPak Inc. SHTP (35)
  • Shumate Industries SHMTE (1)
  • Sibling Group Holdings Inc. SIBE (55)
  • Sierra Gold Corp. SGCP (2)
  • Signature Devices Inc. SDVI (9)
  • Silver Dragon Resources Inc. SDRG (1)
  • Silver Falcon Mining Inc. SFMI (1)
  • SilverSun Technologies Inc. SSNT (30)
  • Simtrol Inc. SMRL (74)
  • Simulated Environment Concepts Inc. SMEV (130)
  • Singlepoint Inc. SING (150)
  • Sino Agro Food Inc. SIAF (1)
  • Sinobiomed Inc. SOBM (4)
  • Sinovac Biotech Ltd SVC (1)
  • Sipp Industries Inc. SIPC (2)
  • Sixty Six Oilfield Services Inc. SSOF (1)
  • Skinny Nutritional Corp. SKNY (19)
  • Skinvisible, Inc. SKVI (41)
  • Sky Petroleum Inc. SKPI (1)
  • SkyPostal Networks Inc. SKPN (66)
  • Small Cap Sentinel (2)
  • Small Cap Sleeper (3)
  • Smallcap Bullets (2)
  • (22)
  • SmallCapVoice (428)
  • Smoky Market Foods Inc. SMKY (9)
  • SocialPicks (1)
  • Sofame Technologies Inc SDW.V (1)
  • Sohm Inc. SHMN (14)
  • Solanex Management Inc. SLNX (15)
  • Solar Energy Initiatives Inc. SNRY (14)
  • Solar Wind Energy Tower Inc. SWET (15)
  • Solarfun Power Holdings Co. Ltd. SOLF (2)
  • Soul and Vibe Interactive Inc. SOUL (14)
  • South Sea Energy Corp. SSGY (7)
  • Soyo Group Inc SOYO (2)
  • SpaceDev Inc. SPDV (5)
  • Sparta Commercial Services Inc. SRCO (31)
  • Speedemissions Inc. SPMI (14)
  • Spicy Pickle Inc SPKL (18)
  • SpongeTech Delivery Systems Inc. SPNG (14)
  • Sports Pouch Beverage Company Inc. SPBV (1)
  • Star Mountain Resources Inc. SMRS (37)
  • Start Scientific Inc. STSC (22)
  • Stealth Technologies, Inc. STTH (3)
  • Stock Market E-News (1)
  • Stock Promoters (4)
  • StockEgg (14)
  • Stocks to Watch (1,951)
  • StocksJournal (2)
  • StockUPTicks (165)
  • Stockwire (6)
  • Strategic American Oil Corp SGCA (32)
  • Stratos Renewables Corp. SRNW (89)
  • StreamTrack Inc. STTK (31)
  • Striker Oil & Gas Inc. SOIS (4)
  • Sun Motor International Inc. SNMO (1)
  • SUN Sports & Entertainment Inc. SSPE (3)
  • Sunshine Biopharma Inc. SBFM (6)
  • Superlattice Power Inc. SLAT (60)
  • SupportSave Solutions, Inc. SSVE (10)
  • Surefect Holdings Inc. SUFH (1)
  • Suspect Detection Systems Inc. SDSS (37)
  • Sweet Success Enterprises Inc. SWTS (35)
  • Swiss Hawk AG SWHKF (1)
  • Symposium Production Corp. SYPJ (1)
  • Tactical Air Defense Services, Inc. TADF (15)
  • Tao Minerals Ltd. TAOL (1)
  • TapImmune, Inc. TPIV (15)
  • Tapinator, Inc. TAPM (26)
  • Taplmmune Inc. TPIM (1)
  • Technology Applications International Inc. NUUU (25)
  • TechPrecision Corp. TPCS (4)
  • Tecton Corp. TTNC (3)
  • Teewinot Life Sciences (9)
  • Teknik Digital Arts Inc. TKNK (10)
  • Telanetix Inc. TNXI (2)
  • Teletouch Communications Inc. TLLE (5)
  • Terax Energy Inc. TEXG (32)
  • Terme Bancorp TMEB (1)
  • Terra Nostra Resources Corp. TNRO (25)
  • The Amergence Group AMNG (8)
  • The Aristocrat Group Corp. ASCC (113)
  • The Bowser Report (68)
  • The Bull Report (32)
  • The Capital Report (5)
  • The DIRECTV Group Inc. DTV (1)
  • The Fight Zone Inc. TFZI (12)
  • The Green Organic Dutchman Holdings Ltd. TGOD (11)
  • The Guitammer Company Inc. GTMM (38)
  • The International Traders Expo (30)
  • The Mobile Star Corp. MBST (7)
  • The Motley Fool (3)
  • The Mundus Group Inc. MNDS (1)
  • The Penny Stock Blog (28)
  • The Principal Structure Fund, Inc. PSF (2)
  • The Tracking Corp. TRKG (1)
  • The UpTurn, Inc. UPTR (20)
  • The Wall Street Savant (24)
  • The Wide Angle (3)
  • Thresher Industries Inc. THRR (15)
  • Tidelands Oil and Gas Corp. TIDE (1)
  • Tiens Biotech Group USA Inc. TBV (1)
  • TMT Capital Corp. TMTP (1)
  • TNI BioTech Inc. TNIB (16)
  • Tombstone Exploration Corp. TMBXF (9)
  • TOMI Environmental Solutions Inc. TOMZ (4)
  • Tootie Pie Company, Inc. TOOT (11)
  • Torchlight Energy Resources, Inc. TRCH (2)
  • TradeShow Marketing Company Inc. TSHO (21)
  • TransWorldNews (4)
  • Tri-Star Holdings Inc. TSHL (31)
  • Trimax Corp. TMXN (31)
  • TripleCrownStocks (9)
  • True 2 Beauty Inc. TRTB (43)
  • TwinTrader (8)
  • TXP Corporation TXPO (1)
  • TZ Ltd. TZL.AX (1)
  • U.S. Mine Makers Inc. USMM (1)
  • uKarma Corporation UKMA (1)
  • Ultitek Ltd. UITK (21)
  • Unbridled Energy Corporation TSX-UNE (21)
  • Unico Inc. UNCO (3)
  • Universal Bioenergy Inc. UBRG (3)
  • Universal Detection Technology UNDT (41)
  • Universal Energy Corp. UVSE (19)
  • Universal Property Development and Acquisition UPDA (4)
  • Universal Tracking Solutions Inc. UTRK (13)
  • Universal Travel Group UTVG (14)
  • UpSNAP Inc. UPSN (1)
  • Uranium Energy Corp. UEC (64)
  • Uranium Hunter Corp. URHN (17)
  • Urex Energy Corp. URXE (1)
  • USA Recycling Industries Inc. USRI (21)
  • USA Superior Energy Inc. USSU (9)
  • Ustelematics Inc. UTLM (27)
  • Utah Uranium Corp. UTUC (2)
  • Utilicraft Aerospace Industries Inc. UITA (2)
  • ValueRich & iValueRich (9)
  • Vaporin Inc. VAPOD (2)
  • VentriPoint Diagnostics Ltd. VPTDF (26)
  • Veritas Pharma Inc. VRTHF (17)
  • Vermillion Inc. VRML (3)
  • Vertical Branding Inc. VBDG (11)
  • VIASPACE, Inc. VSPC (185)
  • Victory Energy Corp. VYEY (29)
  • Victory Square Technologies Inc. VSQTF (2)
  • Vidshadow Inc. VSHD (1)
  • View Systems Inc. VSYM (16)
  • Viper Networks Inc. VPER (2)
  • Viral Genetics Inc. VRAL (3)
  • Viropro International Inc. VPRO (2)
  • VirTra Systems Inc. VTSI (22)
  • Viscount Systems Inc. VSYS (27)
  • visionGATEWAY Inc. VGWA (1)
  • VistaGen Therapeutics Inc. VSTA (104)
  • Visualant Inc. VSUL (5)
  • Vital Products Inc. VTLP (5)
  • Viyya Technologies Inc. VYON (2)
  • VizStar Inc VIZS (24)
  • Voiceserve Inc. VSRV (18)
  • Vortex Resources Corp. VTEX (7)
  • Vsurance Inc. VSUR (3)
  • Vyteris Inc. VYHN (1)
  • W2 Energy Inc. WWEN (13)
  • Wall Street News Alert (76)
  • WallStreetGrapevine (12)
  • WaterPure International Inc. WPUR (4)
  • Wave Systems Corp. WAVX (5)
  • Week in Review (2)
  • Well Power Inc. WPWR (77)
  • Wescorp Energy Inc. WSCE (18)
  • West Canyon Energy Corp. WCYO (1)
  • Western Standard Energy Corp. WSEG (7)
  • Who's Your Daddy Inc. WYDI (7)
  • WikiLoan Inc. WKLI (14)
  • Wind Energy America Inc. WNEA (3)
  • Wisdom Homes of America Inc. WOFA (15)
  • Wits Basin Precious Minerals Inc. WITM (2)
  • Woize International Ltd. WOIZ (1)
  • WordLogic Corp. WLGC (40)
  • Workstream Inc. WSTM (9)
  • WorldWater & Solar Technologies Corp. WWAT (10)
  • Worldwide Energy and Manufacturing WEMU (12)
  • Worldwide Manufacturing USA Inc. WWMU (6)
  • WRIT Media Group Inc. WRIT (36)
  • X-Change Corp. (XCHC) (2)
  • Xaar Plc XAARF (1)
  • Xenomics Inc. XNOM (1)
  • XsunX Inc. XSNX (17)
  • XZERES Corp. XPWR (2)
  • Younger America YNGR (13)
  • Zacks Investment Research (11)
  • ZAGG Inc. ZAGG (9)
  • Zaldiva Inc. ZLDV (3)
  • ZAP ZAAP (15)
  • ZBB Energy Corp ZBB (7)
  • Zenosense Inc. ZENO (53)
  • Zentric Inc. ZNTR (14)
  • Zevotek Inc. ZVTK (8)
  • Zinc One Resources Inc. ZZZOF (7)
  • Znomics Inc. ZNOM (3)
  • Newsletter Signup

    Stay ahead of the pack with QualityStocks and receive "The QualityStocks Daily", our summary formatted newsletter containing stock tips from hundreds of online investment newsletters.

    Rotate your device 90° to view site.